Shandong Pharmaceutical Glass Co., Ltd. Class A

Shandong Pharmaceutical Glass Co., Ltd. Class A

SSSE:600529
18.03
CNY
-0.08
(-0.44%)
1.00EPS
18.11P/E
12.06BMarket Cap
Apr 27Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.09
3.32
3.39
4.1
3.93
4.33
5.02
5.77
6.49
6.98
7.19
7.39
6.75
6.57
Basic EPS, GAAP
0.24
0.24
0.29
0.38
0.44
0.6
0.77
0.95
0.99
1.03
1.17
1.42
1.04
1
Free Cash Flow per Basic Share
0.24
0.26
0.46
0.62
0.41
0.2
0.01
0.05
-0.1
-0.76
0.57
0.78
0.52
- -
Dividend per Share
0.08
0.09
0.09
0.21
0.1
0.17
0.21
0.3
0.3
0.3
0.3
0.7
0.56
0.28
Book Value per Share
4.02
4.2
4.42
5.12
5.46
5.93
6.5
7.15
7.85
10.49
11.35
12.07
12.5
12.8
Tangible Book Value per Share
3.87
4.03
4.24
4.95
5.27
5.67
6.21
6.81
7.52
10.1
10.97
11.69
12.13
12.42
Basic Weighted Avg Shares
500
509
509
502
593
597
596
594
597
600
663
664
663
665
Sales/Revenue/Turnover
1,545
1,691
1,723
2,057
2,330
2,585
2,992
3,427
3,875
4,187
4,771
4,905
4,474
4,371
Operating Margin (%)
12.86
10.93
13.78
15.64
14.23
16.79
18.42
20.97
18.89
16.89
18.84
22.44
21.16
21.01
Depreciation Expense
128
143
138
136
146
147
169
218
241
295
325
385
395
- -
Net Income, GAAP
122
125
145
190
263
358
459
564
591
618
776
943
690
667
Effective Tax Rate (%)
25.57
26.57
25.93
20.99
15.31
16.24
16
13.63
14.18
12.68
14.82
15.11
17
17.74
Profit Margin (%)
7.92
7.37
8.44
9.22
11.27
13.86
15.33
16.47
15.25
14.77
16.26
19.23
15.41
15.27
Working Capital
741
834
921
1,670
1,850
1,927
1,750
1,839
1,656
3,557
3,819
3,980
4,411
4,672
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
23
21
Total Equity
2,030
2,126
2,237
3,044
3,250
3,526
3,868
4,256
4,670
6,962
7,535
8,008
8,295
8,496
Return on Invested Capital (%)
5.84
5.83
6.62
7.71
8.65
11.26
13.44
14.43
13.46
10.74
10.84
12.24
8.56
- -
Return on Capital (%)
6.05
5.93
6.63
7.19
8.31
10.53
12.37
13.85
13.19
10.59
10.7
12.13
8.45
- -
Return on Common Equity (%)
6.16
6.02
6.69
7.19
8.35
10.57
12.41
13.9
13.24
10.63
10.7
12.13
8.46
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
15
17
17
LT Borrowings
- -
- -
- -
LT Finance Leases
27
23
21
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
664
664
664
Market Capitalization
12,290
12,244
12,058

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
6,107
6,126
6,096
Cash, Cash Equivalents & STI
2,741
2,783
2,717
Accounts Receivable, Net
1,009
871
819
Inventories
1,671
1,734
1,841
Total Current Liabilities
1,612
1,440
1,425
Payables & Accruals
- -
- -
- -
ST Debt
15
17
17
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.79%
15.38%
3.58%
Free Cash Flow
39.44%
42.04%
-33.29%
Net Income, GAAP
18.59%
5.9%
-26.87%
Sales/Revenue/Turnover
10.3%
5.82%
-8.78%
Total Cash Common Dividend
- -
- -
-20.28%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,227
1,318
1,239
1,080
4,905
2025
1,171
1,079
1,102
1,122
4,474
2026
1,219
1,061
969
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.33
0.38
0.37
0.34
1.42
2025
0.34
0.22
- -
0.22
1.04
2026
0.3
0.26
0.23
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.3
0.7
2025
- -
- -
- -
- -
0.56
2026
- -
- -
0.28
- -
- -

Company Description

CEO
Jun Zhang
Full Time Employees
6,775
Sector
Process industries
Industry
Containers/Packaging
Address
Yaobo Road Zibo SD China 256100
IPO Date
Jun 3, 2002
Business
Shandong Pharmaceutical Glass Co., Ltd. (600529.SS) manufactures pharmaceutical primary packaging products, including molded and tubular glass vials, ampoules, bottles, jars, and prefillable syringes; butyl rubber closures such as stoppers, plungers, and seals; and aluminum-plastic caps and dropper assemblies. The company, founded in 1970 and headquartered in Zibo, Shandong Province, China, operates five production bases across China and exports to Europe, the United States, Russia, Japan, Korea, Southeast Asia, and other international markets, serving pharmaceutical, food, beverage, and cosmetics industries. It holds the leading position in China for production output, market share, and economic benefits in pharmaceutical glass packaging, with integrated offerings of glass containers, rubber components, and closures. In recent developments, the company reported record Q1 2024 revenue of RMB 650 million, up 15% year-over-year, driven by strong demand for vials (60% of revenue), ampoules (25%), and IV solutions (15%), alongside increased R&D investment reaching RMB 120 million in 2023 for eco-friendly products and new launches; it expanded international sales targeting 25% growth via 10 new markets and RMB 200 million in production upgrades, while canceling a prior acquisition of Yiyuan Xinyuan Logistics in 2025 and earning recognitions like national enterprise technology center status.